Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12590| Title: | The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. | Austin Authors: | Vella, Laura J;Andrews, Miles C;Pasam, Anupama;Woods, Katherine;Behren, Andreas;Cebon, Jonathan S | Affiliation: | Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia | Issue Date: | 3-Jul-2014 | Publication information: | Oncoimmunology 2014; 3(7): e946367 | Abstract: | Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required. | Gov't Doc #: | 25610732 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/12590 | DOI: | 10.4161/21624011.2014.946367 | Journal: | Oncoimmunology | URL: | https://pubmed.ncbi.nlm.nih.gov/25610732 | Type: | Journal Article | Subjects: | BRAF MEK T-lymphocytes dendritic cells melanoma |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.